NCT07271485

Propranolol for Misophonia

Randomized, Placebo-Controlled Pilot Study of Propranolol for Treating Misophonia

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Bloom Mental Health, LLC · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The primary goal of this study is to investigate whether a one-time dose of 20 mg oral propranolol can temporarily reduce the adverse emotional and physical symptoms triggered by misophonia. The secondary goals of this study are: 1. Determine potential predictors of response to propranolol treatment, including demographic factors, baseline symptom severity, psychometric instrument item responses, and physiological characteristics. 2. Evaluate the safety and tolerability of propranolol in individuals with misophonia.

Conditions

• Misophonia
• Propanolol
• Misophonia Treatment

Interventions

Type	Name	Description
DRUG	propranolol	A one-time dose of 20 mg propranolol
DRUG	Placebo	A dose of placebo taken orally

Timeline

• Start date: 2025-12-19
• Primary completion: 2026-12-19
• Completion: 2026-12-19
• First posted: 2025-12-09
• Last updated: 2025-12-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study